Antibody Discovery - Market Insights, Competitive Landscape, and Market Forecast - 2032

Antibody Discovery Market by Service Type (Antigen & Epitope Design, Antibody Screening & Selection, Antibody Engineering & Optimization, Antibody Characterization & Validation, and Others), Antibody Type (Monoclonal Antibodies (mAbs), Bispecific Antibodies, Antibody Drug Conjugates, and Others), Application (Therapeutics, Diagnostics, and Research), Source (Human, Humanized, and Others), End-Users (Biopharmaceutical and Pharmaceutical Companies, Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of chronic diseases and increasing demand for biological therapies.

The antibody discovery market was valued at USD 1.79 billion in 2024, growing at a CAGR of 10.12% during the forecast period from 2025 to 2032 to reach USD 3.86 billion by 2032. The antibody discovery market is growing due to the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular and neurological disorders. Biologics such as monoclonal antibodies and cell therapies offer targeted treatment, driving demand over traditional drugs. Increased drug development by biotech and pharma firms, along with the growing trend of outsourcing discovery services to CROs for faster, efficient development, is further boosting the market. These factors are creating a strong foundation for sustained market growth from 2025 to 2032.

Antibody Discovery Market Dynamics:

The growing prevalence of chronic diseases is expected to drive AI in the clinical trial market. According to GLOBOCAN (2023), approximately 20 million new cancer cases were reported in 2022, with this number projected to rise to 32.6 million by 2045 around the world.

As per the data from the World Health Organization (2024), in the WHO Eastern Mediterranean Region, over 788,000 cancer diagnoses were recorded in 2022. This figure was anticipated to double to approximately 1.57 million cases by 2045. This escalating cancer burden is fueling demand for biologics, which are preferred over traditional small-molecule drugs due to their high specificity and lower off-target toxicity in cancer treatment. Antibody discovery is critical in the development of these biological therapies, thereby boosting the market of antibody discovery market across the world.

Similarly, the global diabetes burden is rising rapidly. The data provided by the International Diabetes Federation (2023), approximately 537 million adults aged 20-79 were living with diabetes in 2021, a number expected to increase to 643 million by 2030 and 783 million by 2045. This growing diabetic population is creating substantial demand for advanced therapies, which require efficient antibody discovery services for the development of innovative biologics, thereby driving the market growth.

According to the World Health Organization (2024), in 2023, epilepsy affected approximately 50 million people worldwide, making it one of the most common neurological disorders. Similarly, depression remains a major global health concern. As per WHO (2023), in 2023, an estimated 280 million people worldwide were living with depression. The increasing prevalence of neurological conditions requires targeted therapies derived from biologic sources, fueling the market growth.

The rising demand for biologic drugs, driven by their high selectivity, potential to slow disease progression, and reduced side effects compared to conventional therapies, is significantly contributing to the expansion of the antibody discovery market. According to data from the Association for Accessible Medicines (2023), more than 90% of prescriptions in the United States were filled with generic or biosimilar medicines in 2022, reflecting the widespread adoption of cost-effective biologic alternatives. This growing reliance on biologics is directly fueling demand for innovative, targeted therapies, which in turn is accelerating the need for advanced antibody discovery technologies. The development of novel therapeutic antibodies is central to meeting this demand, positioning the antibody discovery market for robust growth.

In response, key industry players are intensifying their focus on strategic collaborations and research partnerships aimed at enhancing antibody discovery capabilities. For example, in February 2025, Alloy Therapeutics Inc. announced a strategic collaboration with Pfizer Inc. to co-develop a next-generation platform designed to improve Pfizer's ability to discover potent, specific, and effective antibodies, particularly against targets that are challenging to address using existing technologies.

However, the complexities and challenges in antibody development and manufacturing, and high development & production costs of antibodies, among others, are some of the key constraints that may limit the growth of the antibody discovery market.

Antibody Discovery Market Segment Analysis:

Antibody Discovery Market by Service Type (Antigen & Epitope Design, Antibody Screening & Selection, Antibody Engineering & Optimization, Antibody Characterization & Validation, and Others), Antibody Type (Monoclonal Antibodies (mAbs), Bispecific Antibodies, Antibody Drug Conjugates, and Others), Application (Therapeutics, Diagnostics, and Research), Source (Human, Humanized, and Others), End-Users (Biopharmaceutical and Pharmaceutical Companies, Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the service type segment of the antibody discovery market, the antibody engineering & optimization category is estimated to account for the largest market share in 2024. The growth of this category is primarily driven by the rising demand for biologic drugs, where antibody engineering plays a critical role in enhancing therapeutic efficacy, safety, and manufacturability.

Antibody engineering involves the modification and refinement of antibodies to improve their functional properties for both therapeutic and diagnostic applications. This includes enhancing binding affinity and specificity to target antigens, increasing molecular stability and half-life, reducing immunogenicity, and optimizing production scalability. These modifications not only improve therapeutic performance but also ensure the antibodies are suitable for large-scale manufacturing and long-term storage, key factors for commercial success.

Antibody engineering and optimization support the development of advanced biologic formats such as bispecific antibodies, antibody fragments (Fab, scFv), nanobodies, and antibody-drug conjugates (ADCs). For example, humanization of murine antibodies helps minimize immune rejection, making therapies safer and more effective for clinical use. A notable case is Gazyva® (obinutuzumab), which was engineered to enhance antibody-dependent cellular cytotoxicity (ADCC) against CD20⁺ lymphoma cells, demonstrating the real-world therapeutic value of antibody optimization.

In response to increasing demand, key players are actively pursuing strategic collaborations to advance antibody engineering capabilities. In June 2025, MAbSilico announced an exclusive partnership with YntoAb Co., Ltd., a leading Korean CRO, to co-develop high-resolution 3D antibody structure prediction tools. This collaboration aims to enable advanced epitope-driven design and customized antibody engineering solutions. Similarly, in September 2024, Isogenica Ltd. and Axxam S.p.A. formed a partnership to deliver specialized VHH antibody engineering services tailored to the needs of biotechnology and pharmaceutical companies.

Furthermore, companies such as Creative Biolabs, ProteoGenix, and others are offering comprehensive antibody engineering services, further accelerating innovation and adoption in this space. Their contributions are playing a key role in positioning the Asia-Pacific region as a growing hub for advanced antibody discovery and development.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of antibody discovery across the globe.

North America is expected to dominate the overall antibody discovery market:

North America is expected to hold the largest share of the antibody discovery market in 2024, driven by several key factors. This dominance can be attributed to several key factors, including the rising prevalence of chronic diseases, substantial investments in R&D for advanced therapies, increasing demand for biologic treatments, a growing number of drug development activities by biotech and pharmaceutical companies, and the development of advanced technologies to efficiently create antibody-based drugs. Collectively, these elements are expected to sustain the region's leading position in the antibody discovery market.

As per the data from GLOBOCAN (2024) revealed that the number of new cancer cases in the U.S. reached 2,380,189 in 2022, with projections suggesting an increase to 2,791,752 cases by 2030. Data from the American Cancer Society (2025) states that approximately 2,041,910 new cancer cases are expected to be diagnosed in 2025 in the United States.

According to the American Heart Association (2024), approximately 9.7 million adults were living with undiagnosed diabetes, while 29.3 million have been diagnosed. Furthermore, 115.9 million Americans were reported to be dealing with pre-diabetes as of 2021. The rising cases of cancer and diabetes in North America are driving the growth of the antibody discovery market by increasing the demand for targeted and personalized therapies, where monoclonal antibodies play a crucial role in improving treatment outcomes. This growing disease burden is prompting greater investment in research and development to discover and optimize novel antibody-based treatments.

According to an article published by the Centers for Disease Control and Prevention (2024), approximately 6.2 million adults were suffering from heart failure in the United States in 2022. The prevalence of coronary heart disease (CHD) is also a major driver of market growth. According to CDC data from June 2024, around 20.5 million Americans were living with CHD as of 2022. Furthermore, an estimated 6.5 million individuals aged 40 and older were diagnosed with peripheral artery disease (PAD) in the same year. Such rising cases of cardiovascular conditions are creating the demand for targeted therapies, which can be developed through antibody discovery.

As per the data from the National Institute of Health (2023), in 2022, it was estimated that more than one in five adults were living with a mental illness (59.3 million), with 21 million people suffering from one major depressive disorder. Similarly, data from the Government of Canada (2023), in 2022, approximately 5 million people were suffering from mental disorders, including major depressive disorders, anxiety, seizures, among others. According to the Centers for Disease Control and Prevention (2024), in 2022, approximately 2.9 million adults aged 18 and older in the U.S. reported having active epilepsy. Such an increasing prevalence of neurological conditions is fueling the growth of the antibody discovery market, as there is a growing need for targeted biologic therapies to address complex disorders such as Alzheimer's, multiple sclerosis, and Parkinson's disease.

Key players are increasingly focusing on technological advancements to accelerate antibody discovery in the region. For example, in October 2024, Absci and Twist Bioscience announced a collaboration to design a novel antibody therapeutic using Absci's generative AI platform and Twist's synthetic DNA technology, combining AI-driven antibody design with high-throughput gene synthesis for efficient testing and validation.

Therefore, the growing incidence of chronic diseases, combined with rapid technological innovation and research partnerships among key players, is positioning North America as a leader in the antibody discovery market.

Antibody Discovery Market Key Players:

Some of the key market players operating in the antibody discovery market include Creative Biolabs, AbCellera Biologics Inc., Twist Bioscience, Thermo Fisher Scientific Inc., Absci Corp., ProteoGenix, Neoncorte Bio, Antibody Design Labs, Adimab, GenScript, Sino Biological, Inc., Carterra, Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Lonza, AvantGen, Aragen Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Biointron Biological Inc., and others.

Recent Developmental Activities in the Antibody Discovery Market:

• In June 2025, Infinimmune, a biotechnology company specializing in human-first antibody discovery and design, launched GLIMPSE-1, a protein language model trained exclusively on native human antibody sequences from millions of paired heavy and light chains of human memory B cells, marking a new approach to therapeutic antibody engineering based on the human adaptive immune system.
• In April 2025, Antibody Solutions announced that single plasma B-cell discovery services have been added to its exclusive Cellestive antibody discovery platform, complementing the existing discovery pathways for activated and memory B-cells.
• In February 2022, Adcentrx Therapeutics, a biotechnology company focused on accelerating antibody-drug conjugate (ADC) development, and AvantGen, a leader in yeast display technology for human antibody discovery and optimization, announced a three-year, multi-target partnership to discover antibodies for novel ADC therapeutic candidates.  

Key takeaways from the antibody discovery market report study:

• Market size analysis for current antibody discovery market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the antibody discovery market.
• Various opportunities available for the other competitors in the antibody discovery market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current antibody discovery market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for the antibody discovery market growth in the future?

Target audience who can benefit from this antibody discovery market report study

• Antibody discovery product providers
• Research organizations and consulting companies
• Antibody discovery-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in antibody discovery
• Various end-users who want to know more about the antibody discovery market and the latest technological developments in the antibody discovery market.

Frequently Asked Questions for the Antibody Discovery Market:

1. What is antibody discovery?

• Antibody discovery is the process of identifying and developing antibodies that specifically bind to target molecules involved in diseases. It involves techniques like hybridoma, phage display, or single B-cell screening to generate and optimize candidate antibodies. These antibodies are then evaluated for their potential use in diagnostics, therapeutics, or research.

2. What is the market for antibody discovery?

• The antibody discovery market was valued at USD 1.79 billion in 2024, growing at a CAGR of 10.12% during the forecast period from 2025 to 2032 to reach USD 3.86 billion by 2032.

3. What are the drivers for the antibody discovery market?

• The antibody discovery market is growing due to the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular and neurological disorders. Biologics such as monoclonal antibodies and cell therapies offer targeted treatment, driving demand over traditional drugs. Increased drug development by biotech and pharma firms, along with the growing trend of outsourcing discovery services to CROs for faster, efficient development, is further boosting the market. These factors are creating a strong foundation for sustained market growth from 2025 to 2032.

4. Who are the key players operating in the antibody discovery market?

• Some of the key market players operating in the antibody discovery market include Creative Biolabs, AbCellera Biologics Inc., Twist Bioscience, Thermo Fisher Scientific Inc., Absci Corp., ProteoGenix, Neoncorte Bio, Antibody Design Labs, Adimab, GenScript, Sino Biological, Inc., Carterra, Inc., WuXi AppTec, Samsung Biologics, Charles River Laboratories, Lonza, AvantGen, Aragen Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Biointron Biological Inc., and others.

5. Which region has the highest share in the antibody discovery market?

• North America is expected to hold the largest share of the antibody discovery market in 2024, driven by several key factors. This dominance can be attributed to several key factors, including the rising prevalence of chronic diseases, substantial investments in R&D for advanced therapies, increasing demand for biologic treatments, a growing number of drug development activities by biotech and pharmaceutical companies, and the development of advanced technologies to efficiently create antibody-based drugs. Collectively, these elements are expected to sustain the region's leading position in the antibody discovery market.

This product will be delivered within 2 business days.